Li Ying, Lv Chengzhi, Dang Lin, Lin Bingjiang, Tao Juan, Zhang Chunlei, Zhou Xiaoyong, Ma Han, Lu Yi, Chen Rong, Li Jinnan, Dou Guanshen, Liang Yunsheng, Liang Yanhua, Shi Yuling
Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.
Department of Dermatology, Dalian Dermatosis Hospital, Dalian, Liaoning, China.
Dermatol Ther (Heidelb). 2024 Apr;14(4):907-918. doi: 10.1007/s13555-024-01134-y. Epub 2024 Mar 27.
Ixekizumab, a monoclonal antibody against interleukin-17A, demonstrated effectiveness in the treatment of psoriasis in a Chinese real-world study that was consistent with previous randomized controlled trials. Here, we report further analyses from this study to explore the effectiveness of ixekizumab for treating patients with psoriasis and the involvement of special body areas (scalp, nail, joint, palmoplantar, or genital areas).
A multicenter, prospective, observational, single-arm, post-marketing surveillance study was conducted in patients aged ≥ 18 years with moderate-to-severe plaque psoriasis and prescribed with ixekizumab in 26 Chinese hospitals. Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores were compared between patients with versus without psoriasis in special body areas in the overall study population and across subgroups by body area.
In total, 612 patients were included. At baseline, most patients (93.6%) had psoriasis involvement in at least one special body area. Overall, patients with psoriasis in special body areas reported a worse quality of life (QoL) than those without. Patients with versus without psoriasis in special body areas achieved a comparable mean reduction from baseline in PASI score (10.9 vs. 9.2 at week 2, and 16.9 vs. 14.7 at week 12, respectively) and DLQI score (6.0 vs. 4.4 at week 2, and 9.9 vs. 7.5 at week 12, respectively); a similar proportion of patients also achieved PASI 50 at week 2, and PASI 75 and PASI 90 at week 12, and a DLQI (0/1) at weeks 2 and 12. Several significantly different results were reported between subgroups, the majority of which favored patients with special body area involvement.
Most patients had psoriasis involvement in a special body area which was associated with worse QoL. Ixekizumab is similarly effective in reducing disease severity and improving QoL in patients with plaque psoriasis across different special body areas.
在一项中国真实世界研究中，抗白细胞介素-17A单克隆抗体司库奇尤单抗在治疗银屑病方面显示出有效性，这与之前的随机对照试验结果一致。在此，我们报告该研究的进一步分析结果，以探讨司库奇尤单抗治疗银屑病患者的有效性以及特殊身体部位（头皮、指甲、关节、掌跖或生殖器部位）的受累情况。
在26家中国医院对年龄≥18岁、患有中度至重度斑块状银屑病且已处方司库奇尤单抗的患者进行了一项多中心、前瞻性、观察性、单臂上市后监测研究。比较了总体研究人群中以及按身体部位划分的亚组中，有和没有特殊身体部位银屑病的患者之间的银屑病面积和严重程度指数（PASI）以及皮肤病生活质量指数（DLQI）评分。
总共纳入了612例患者。在基线时，大多数患者（93.6%）的银屑病累及至少一个特殊身体部位。总体而言，特殊身体部位有银屑病的患者报告的生活质量（QoL）比没有的患者更差。特殊身体部位有和没有银屑病的患者在第2周时PASI评分从基线的平均降低幅度相当（分别为10.9和9.2），在第12周时分别为16.9和14.7；DLQI评分在第2周时分别为6.0和4.4，在第12周时分别为9.9和7.5；在第2周和第12周时，达到PASI 50、PASI 75和PASI 90以及DLQI（0/1）的患者比例相似。亚组之间报告了一些显著不同的结果，其中大多数结果有利于有特殊身体部位受累的患者。
大多数患者的银屑病累及特殊身体部位，这与较差的生活质量相关。司库奇尤单抗在降低不同特殊身体部位斑块状银屑病患者的疾病严重程度和改善生活质量方面同样有效。
